...
search icon
vrdn-img

Viridian Therapeutics Inc Share Price

VRDN
NAQ
$29.19
-$0.46
(-1.55%)
1D
Industry: Biotechnology Sector: Health Care

Viridian Therapeutics Inc Analyst Forecast

Viridian Therapeutics Inc Share Price Chart

Viridian Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.03B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.21M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.9 L
$34.29 H
$29.19

About Viridian Therapeutics Inc, Common Stock

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Viridian Therapeutics Inc Stock Returns

Time FrameVRDNSectorS&P500
1-Week Return-0.44%-1.58%-0.31%
1-Month Return-2.89%-0.69%-1.99%
3-Month Return-10.46%1.39%-1.32%
6-Month Return47.28%12.33%4.02%
1-Year Return87.36%4.46%21.01%
3-Year Return2.75%24.25%75.88%
5-Year Return64.27%35.72%74.21%
10-Year Return-77.64%129.28%240.86%

Viridian Therapeutics Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue2.96M1.77M314.00K302.00K70.85M[{"date":"2021-12-31","value":4.18,"profit":true},{"date":"2022-12-31","value":2.5,"profit":true},{"date":"2023-12-31","value":0.44,"profit":true},{"date":"2024-12-31","value":0.43,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Cost of Revenue620.00K755.00K1.32M1.24M1.16M[{"date":"2021-12-31","value":46.9,"profit":true},{"date":"2022-12-31","value":57.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.8,"profit":true},{"date":"2025-12-31","value":87.75,"profit":true}]
Gross Profit2.96M1.77M314.00K302.00K69.69M[{"date":"2021-12-31","value":4.25,"profit":true},{"date":"2022-12-31","value":2.54,"profit":true},{"date":"2023-12-31","value":0.45,"profit":true},{"date":"2024-12-31","value":0.43,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%98.36%[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":98.36,"profit":true}]
Operating Expenses82.69M136.08M254.76M299.34M433.08M[{"date":"2021-12-31","value":19.09,"profit":true},{"date":"2022-12-31","value":31.42,"profit":true},{"date":"2023-12-31","value":58.83,"profit":true},{"date":"2024-12-31","value":69.12,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(79.73M)(134.30M)(254.45M)(299.04M)(363.39M)[{"date":"2021-12-31","value":-7972800000,"profit":false},{"date":"2022-12-31","value":-13430400000,"profit":false},{"date":"2023-12-31","value":-25445000000,"profit":false},{"date":"2024-12-31","value":-29903500000,"profit":false},{"date":"2025-12-31","value":-36339500000,"profit":false}]
Total Non-Operating Income/Expense630.00K8.86M32.09M58.17M43.24M[{"date":"2021-12-31","value":1.08,"profit":true},{"date":"2022-12-31","value":15.23,"profit":true},{"date":"2023-12-31","value":55.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":74.34,"profit":true}]
Pre-Tax Income(79.41M)(129.87M)(237.73M)(269.95M)(342.60M)[{"date":"2021-12-31","value":-7941300000,"profit":false},{"date":"2022-12-31","value":-12987400000,"profit":false},{"date":"2023-12-31","value":-23773400000,"profit":false},{"date":"2024-12-31","value":-26994900000,"profit":false},{"date":"2025-12-31","value":-34260100000,"profit":false}]
Income Taxes3.00K(4.43M)18.56M(269.95M)-[{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":-23.86,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1454.23,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(79.42M)(125.44M)(256.30M)--[{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(79.56M)(130.11M)(216.66M)(269.95M)(342.60M)[{"date":"2021-12-31","value":-7956200000,"profit":false},{"date":"2022-12-31","value":-13010700000,"profit":false},{"date":"2023-12-31","value":-21665900000,"profit":false},{"date":"2024-12-31","value":-26994900000,"profit":false},{"date":"2025-12-31","value":-34260100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.60M)[{"date":"2021-12-31","value":-7941300000,"profit":false},{"date":"2022-12-31","value":-12987400000,"profit":false},{"date":"2023-12-31","value":-23773400000,"profit":false},{"date":"2024-12-31","value":-26994900000,"profit":false},{"date":"2025-12-31","value":-34260100000,"profit":false}]
EPS (Diluted)(7.69)(4.03)(5.32)(3.77)(3.29)[{"date":"2021-12-31","value":-769,"profit":false},{"date":"2022-12-31","value":-403,"profit":false},{"date":"2023-12-31","value":-532,"profit":false},{"date":"2024-12-31","value":-377.46,"profit":false},{"date":"2025-12-31","value":-328.9,"profit":false}]

Viridian Therapeutics Inc Ratios

Viridian Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

VRDN
Cash Ratio 12.37
Current Ratio 12.65

Viridian Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VRDN
ROA (LTM) -27.67%
ROE (LTM) -49.16%

Viridian Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VRDN
Debt Ratio Lower is generally better. Negative is bad. 0.20
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.80

Viridian Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VRDN
Trailing PE NM
Forward PE NM
P/S (TTM) 42.77
P/B 5.14
Price/FCF NM
EV/R 33.01
EV/Ebitda NM

FAQs

What is Viridian Therapeutics Inc share price today?

Viridian Therapeutics Inc (VRDN) share price today is $29.19

Can Indians buy Viridian Therapeutics Inc shares?

Yes, Indians can buy shares of Viridian Therapeutics Inc (VRDN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRDN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Viridian Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Viridian Therapeutics Inc (VRDN) via the Vested app. You can start investing in Viridian Therapeutics Inc (VRDN) with a minimum investment of $1.

How to invest in Viridian Therapeutics Inc shares from India?

You can invest in shares of Viridian Therapeutics Inc (VRDN) via Vested in three simple steps:

  • Click on Sign Up or Invest in VRDN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Viridian Therapeutics Inc shares
What is Viridian Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Viridian Therapeutics Inc (VRDN) is $34.29. The 52-week low price of Viridian Therapeutics Inc (VRDN) is $9.9.

What is Viridian Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Viridian Therapeutics Inc (VRDN) is

What is Viridian Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Viridian Therapeutics Inc (VRDN) is 5.14

What is Viridian Therapeutics Inc dividend yield?

The dividend yield of Viridian Therapeutics Inc (VRDN) is 0.00%

What is the Market Cap of Viridian Therapeutics Inc?

The market capitalization of Viridian Therapeutics Inc (VRDN) is $3.03B

What is Viridian Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Viridian Therapeutics Inc is VRDN

How Can Investors Use Viridian Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Viridian Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Viridian Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Viridian Therapeutics Inc shares for Indian investors?

When investing in Viridian Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Viridian Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Viridian Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Viridian Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Viridian Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top